Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 12 of 12 entries
View as:

A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT04674813 Org: User:
Start: 02/24/21 End: 06/07/25 Due: 06/07/26

A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT04394650 Org: User:
Start: 08/18/20 End: 07/03/24 Due: 07/03/25

Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

Phase: N/A Priority: Normal
NCT ID: NCT03436771 Org: User:
Start: 02/19/18 End: 07/20/18 Due: 07/20/19

Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol

Phase: N/A Priority: Normal
NCT ID: NCT04400591 Org: User:
Start: - End: - Due: -

Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)

Phase: N/A Priority: Normal
NCT ID: NCT02535364 Org: User:
Start: 08/21/15 End: 09/01/17 Due: 09/01/18

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT03430011 Org: User:
Start: 02/01/18 End: 03/30/23 Due: 03/30/24

Long-Term Follow-up Study for Patients Previously Treated With JCAR015

Phase: N/A Priority: Normal
NCT ID: NCT02813252 Org: User:
Start: 08/30/16 End: 10/22/21 Due: 10/22/22

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

Phase: N/A Priority: Normal
NCT ID: NCT03483103 Org: User:
Start: 07/27/18 End: 12/01/22 Due: 12/01/23

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

Phase: N/A Priority: Normal
NCT ID: NCT02631044 Org: User:
Start: 01/06/16 End: 05/16/24 Due: 05/16/25

A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04231747 Org: User:
Start: 05/21/20 End: 02/01/24 Due: 02/01/25

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

Phase: N/A Priority: Normal
NCT ID: NCT03744676 Org: User:
Start: 11/29/18 End: 09/22/23 Due: 09/22/24

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Phase: N/A Priority: Normal
NCT ID: NCT03331198 Org: User:
Start: 11/27/17 End: 11/26/27 Due: 11/26/28